December 3, 2025 — As the world is coming around to the understanding that public health policy cannot neglect the need for obesity treatment, a question hangs in the air. What does this mean for obesity prevention strategies? This question – together with fast-changing market realities – begs another question. Will prevention policy or market dynamics reduce obesity more? […]
December 2, 2025 — This is huge news and we’ve been waiting for it a very long time. For the first time ever, the World Health Organization (WHO) is embracing obesity treatment in a new global guidance issued yesterday. From the head of WHO, Director-General Tedros Adhanom Ghebreyesus, came words we wondered if we would ever hear: “Our new […]
November 26, 2025 — It seems like some good news is overdue for Novo Nordisk. So the topline report of a phase two study with amycretin that looks like a plausible win is especially welcome. The results at hand come from a 36-week placebo controlled study with a wide range of oral and injection doses in persons with type […]
November 21, 2025 — The sprint to the finish for orforglipron is picking up pace with a pivotal trial in obesity and diabetes published yesterday in The Lancet. Things are looking good for this relatively simple GLP-1 agonist in a tablet. The presentation of these results from ATTAIN-2 were a highlight of ObesityWeek earlier this month, but having this […]
November 15, 2025 — Anyone who thought this would be a passing thing was way off the mark. As prices of GLP-1 medicines are falling, their use is rising. As Stat News notes, we now have more people using these medicines than the entire population of Texas. This rising trend occurs against a background of costs that are still […]
November 12, 2025 — This is a perilous and exciting time for investing in obesity innovation as the market for treating this disease advances dramatically. On the side of excitement, we note that the David Wainer in the Wall Street Journal predicts that “obesity drugs are about to go mass market.” Perilous for Novo On the side of peril, […]
November 11, 2025 — Just skimming headlines about new medicines for obesity and surgery, comparisons seem to be a dominant theme. Some of these headlines tell us surgery is more cost-effective or delivers more durable results. Some of that is certainly true. But the deeper truth surfaces this week in JAMA and JAMA Network Open. Clinical experience and, increasingly, […]
November 6, 2025 — At ObesityWeek in Atlanta, people are speculating about innovations that health professionals in general practice can embrace widely. We’re getting a good look at two candidates to become the GP GLP-1. Providing real obesity care and prescribing these medicines for more than a small portion of patients who need them is far from the norm. […]
November 3, 2025 — A year ago, we had these wonderful new obesity medicines – semaglutide and tirzepatide – and nobody could get them. Demand had outstripped supply and we had a shortage. Earlier this year, the supply shortage for both drugs resolved, but now we face the same situation because of a different shortage. There is a shortage […]
October 24, 2025 — A new study in Lancet tells us that we need a fundamental reframing of the medical benefits semaglutide can bring to a growing number of people around the world. In the simplest terms, researchers have found that the heart benefits of semaglutide actually have relatively little to do with weight loss. Professor John Deanfield was […]
